{"id":2201,"date":"2025-12-12T07:00:18","date_gmt":"2025-12-11T23:00:18","guid":{"rendered":"https:\/\/www.hanchorbio.com\/news\/hanchorbio-announces-oral-presentation-of-hcb101-at-the-esmo-immuno-oncology-congress-2025\/"},"modified":"2025-12-12T07:00:18","modified_gmt":"2025-12-11T23:00:18","slug":"hanchorbio-announces-oral-presentation-of-hcb101-at-the-esmo-immuno-oncology-congress-2025","status":"publish","type":"news","link":"https:\/\/www.hanchorbio.com\/zh-hans\/news\/hanchorbio-announces-oral-presentation-of-hcb101-at-the-esmo-immuno-oncology-congress-2025\/","title":{"rendered":"HanchorBio Announces Oral Presentation of HCB101 at the  ESMO Immuno-Oncology Congress 2025"},"content":{"rendered":"<h3><strong>HanchorBio Announces Oral Presentation of HCB101 at the\u00a0<\/strong><strong>ESMO Immuno-Oncology Congress 2025<\/strong><\/h3>\n<p><em>International debut underscores emerging role for macrophage checkpoint therapy in gastric cancer, triple-negative breast cancer, and other hard-to-treat solid tumors<\/em><\/p>\n<p><strong>[Taipei, Shanghai, and San Francisco | December 12, 2025]<\/strong> \u2013HanchorBio Inc. (TPEx: 7827), a global clinical-stage biotechnology company advancing next-generation immunotherapies for oncology and autoimmune diseases, announced that new clinical data from its flagship macrophage-checkpoint program, HCB101, has been selected for a mini oral presentation at the ESMO Immuno-Oncology Congress 2025 in London, United Kingdom. Only 26 abstracts were chosen for mini-oral presentation this year, marking a major milestone for HanchorBio as it delivers its first-ever oral presentation of clinical data at an international oncology congress, following its prior preclinical oral presentation of HCB101 at SITC 2022.<\/p>\n<p>&nbsp;<\/p>\n<p>The ESMO Immuno-Oncology Congress is Europe\u2019s premier meeting dedicated exclusively to immuno-oncology science, distinct from the broader ESMO Annual Congress. While the annual ESMO meeting spans all oncology disciplines, ESMO-IO focuses on immune mechanisms, translational innovation, and next-generation therapeutic strategies across innate and adaptive immunity.<\/p>\n<p>&nbsp;<\/p>\n<p><strong>Presentation Details:<\/strong><\/p>\n<p><strong>Abstract ID:<\/strong>\u00a0 242MO<\/p>\n<p><strong>Title:<\/strong> <em>HCB101, a Differentiated SIRP\u03b1 Fusion Protein, Demonstrates Favorable Safety and Early Antitumor Activity Across Solid Tumors and Lymphoma<\/em><\/p>\n<p><strong>First Author:<\/strong> Dr. Fangling Ning, Affiliated Hospital of Binzhou Medical University<\/p>\n<p><strong>Date \/ Time:<\/strong> 11 December 2025 \/ 11:45 \u2013 12:45 GMT<\/p>\n<p><strong>Location:<\/strong> Whittle Room, Queen Elizabeth II Centre, London<\/p>\n<p><strong>Presenter:<\/strong> Alvin Luk, PhD, MBA, CCRA &#8211; President &amp; CMO (Group) and CEO (U.S.A.), <em>TIME100 <\/em>Health 2025 Honoree<\/p>\n<p><img loading=\"lazy\" decoding=\"async\" class=\"alignnone size-full wp-image-1820\" src=\"https:\/\/www.hanchorbio.com\/wp-content\/uploads\/HanchorBio-Announces-Oral-Presentation-of-HCB101-at-ESMO.jpg\" alt=\"HanchorBio-Announces-Oral-Presentation-of-HCB101-at-the- ESMO-Immuno-Oncology-Congress-2025\" width=\"1000\" height=\"250\" srcset=\"https:\/\/www.hanchorbio.com\/wp-content\/uploads\/HanchorBio-Announces-Oral-Presentation-of-HCB101-at-ESMO.jpg 1000w, https:\/\/www.hanchorbio.com\/wp-content\/uploads\/HanchorBio-Announces-Oral-Presentation-of-HCB101-at-ESMO-300x75.jpg 300w, https:\/\/www.hanchorbio.com\/wp-content\/uploads\/HanchorBio-Announces-Oral-Presentation-of-HCB101-at-ESMO-150x37.jpg 150w\" sizes=\"auto, (max-width: 1000px) 100vw, 1000px\" \/><\/p>\n<p>&nbsp;<\/p>\n<p>\u201cFor nearly a decade, CD47 therapies were held back not by flawed biology but by flawed molecules, which struggled to balance safety and efficacy at the same time, especially in immunologically cold tumors,\u201d said <strong>Scott Liu, PhD, Founder, Chairman, and CEO of HanchorBio<\/strong>. \u00a0\u201cHCB101 was engineered from the ground up to solve that problem. Using AI-guided structural modeling, we identified three core mutations that reshape SIRP\u03b1\u2019s interaction with CD47, allowing us to combine the strengths of first- and second-generation approaches into a single, differentiated molecule. Being selected as one of only 26 mini-oral presentations at ESMO Immuno-Oncology reinforces the field\u2019s recognition of this differentiation. With its clean safety profile, strong target engagement, and early activity in cold tumors, HCB101 is emerging as a true macrophage-checkpoint backbone \u2013 much like PD-1\/PD-L1 transformed T-cell oncology.\u201d<\/p>\n<p><strong><u>Key Findings Highlighted in the Mini-Oral<\/u><\/strong><\/p>\n<p><strong>Monotherapy (HCB101-101; NCT05892718)<\/strong><\/p>\n<ul>\n<li>Clean, cytopenia-sparing safety across 12 cohorts up to 36 mg\/kg QW<\/li>\n<li>No bleeding events or immune-related toxicities, with the majority of treatment-related adverse events being Grade 1-2<\/li>\n<li>Linear PK (T<sub>1\/2 <\/sub>~3 days) with receptor occupancy (RO) &gt;90% at \u22658 mg\/kg<\/li>\n<li>Durable antitumor activity, including confirmed PRs in:\n<ul>\n<li>HNSCC -Head and neck squamous cell carcinoma (~42% tumor regression, \u226532 weeks)<\/li>\n<li>MZL &#8211; Marginal zone lymphoma (~89% tumor regression, \u226516 weeks)<\/li>\n<\/ul>\n<\/li>\n<li>Stable disease \u22654-9 months across colorectal cancer (CRC), ovarian cancer, non-small cell lung cancer (NSCLC), and sarcoma<\/li>\n<\/ul>\n<p><img loading=\"lazy\" decoding=\"async\" class=\"alignnone size-full wp-image-1822\" src=\"https:\/\/www.hanchorbio.com\/wp-content\/uploads\/HCB101-shows-clean-cytopenia-sparing-safety.jpg\" alt=\"HCB101-Shows-Clean- Cytopenia-Sparing-Safety\" width=\"304\" height=\"186\" srcset=\"https:\/\/www.hanchorbio.com\/wp-content\/uploads\/HCB101-shows-clean-cytopenia-sparing-safety.jpg 304w, https:\/\/www.hanchorbio.com\/wp-content\/uploads\/HCB101-shows-clean-cytopenia-sparing-safety-300x184.jpg 300w, https:\/\/www.hanchorbio.com\/wp-content\/uploads\/HCB101-shows-clean-cytopenia-sparing-safety-150x92.jpg 150w\" sizes=\"auto, (max-width: 304px) 100vw, 304px\" \/><\/p>\n<p>&nbsp;<\/p>\n<p><strong>Combination Therapy (HCB101-201; NCT06771622)<\/strong><\/p>\n<ul>\n<li>Well-tolerated across gastric cancer (GC), triple-negative breast cancer (TNBC), CRC, and HNSCC<\/li>\n<li>No new safety signals across all evaluated combinations<\/li>\n<li>Cytopenias fully attributable to chemotherapy, not HCB101<\/li>\n<li>2L GC:\n<ul>\n<li>58.3% ORR (7\/12) and 100% DCR<\/li>\n<li>Tumor shrinkage up to 78.2%<\/li>\n<\/ul>\n<\/li>\n<li>1L HER2+ GC: 33% ORR (1\/3)<\/li>\n<li>1L TNBC: 33% ORR (2\/6) and 100% DCR<\/li>\n<\/ul>\n<p>&nbsp;<\/p>\n<p><strong>Alvin Luk, PhD, MBA, CCRA, President &amp; Chief Medical Officer (Group) and Chief Executive Officer (U.S.A.) of HanchorBio<\/strong>, added, \u201cThe early efficacy signals from HCB101 are unusually compelling for this stage of development. In second-line GC, where standard therapy achieves an ORR of about 28%, HCB101 combinations exceed 58% ORR, with 100% disease control, and tumor reduction approaching 78%. These results are not incremental; they meaningfully exceed expectations and reflect robust macrophage checkpoint engagement. With clean safety and sustained receptor occupancy, the data give us confidence to anchor development in second-line disease and expand into first-line and perioperative settings where depth and durability of response matter most.\u201d<\/p>\n<p>&nbsp;<\/p>\n<p><strong>About HCB101: A Next-Generation SIRP\u03b1 Fc-Fusion Protein<\/strong><\/p>\n<p>HCB101 is a 3.5<sup>th<\/sup>-generation engineered SIRP\u03b1-Fc fusion protein with an intact IgG4 Fc backbone, developed using HanchorBio\u2019s FBDB\u2122 platform to selectively target CD47 while minimizing low red blood cell binding. This design avoids the anemia and thrombocytopenia that limited early anti-CD47 programs, while preserving potent macrophage activation and downstream T-cell engagement. \u00a0Key differentiators include:<\/p>\n<ul>\n<li>Cytopenia-sparing safety up to 30-36 mg\/kg<\/li>\n<li>Receptor occupancy (RO) &gt;90% at clinically active exposures<\/li>\n<li>Strong macrophage and downstream T-cell activation<\/li>\n<li>Broad antitumor activity across &gt;80 PDX\/CDX models and multiple clinical tumor types<\/li>\n<li>Robust early combination efficacy in historically CD47-resistant tumors<\/li>\n<\/ul>\n<p>Unlike earlier approaches, HCB101\u2019s safety, target selectivity, and RO profile support its use as a macrophage-checkpoint backbone \u2013 analogous to how PD-1\/PD-L1 inhibitors function as foundational T-cell backbones in oncology. HCB101 is designed for broad combinability across established and emerging treatment modalities, including:<\/p>\n<ul>\n<li>Chemotherapy<\/li>\n<li>Radiation therapy<\/li>\n<li>Antibody-drug conjugates (ADCs)<\/li>\n<li>Anti-PD-1\/anti-PD-L1 checkpoint inhibitors<\/li>\n<li>Anti-VEGF inhibitors<\/li>\n<li>Anti-EGFR therapies<\/li>\n<li>Anti-HER2 regimens<\/li>\n<\/ul>\n<p>This versatility positions HCB101 as a modular, next-generational immuno-oncology component capable of enhancing the efficacy of multiple therapeutic backbones across solid tumors and hematologic malignancies.<\/p>\n<p>&nbsp;<\/p>\n<h3><strong>\u6f22\u5eb7\u751f\u6280<\/strong><strong>HCB101<\/strong><strong>\u7372\u9078<\/strong><strong>2025<\/strong><strong>\u5e74<\/strong><strong>ESMO<\/strong><strong>\u514d\u75ab\u816b\u7624\u5b78\u5927\u6703\u53e3\u982d\u5831\u544a<\/strong><\/h3>\n<p><em>\u570b\u969b\u9996\u79c0\u5f70\u986f\u5de8\u566c\u7d30\u80de\u6aa2\u67e5\u9ede\u7642\u6cd5\u5728\u80c3\u764c\u3001\u4e09\u9670\u6027\u4e73\u764c\u7b49\u96e3\u6cbb\u5be6\u9ad4\u7624\u4e2d\u7684\u65b0\u8208\u6f5b\u529b<\/em><\/p>\n<p>[\u81fa\u5317\uff0c\u4e0a\u6d77\uff0c\u820a\u91d1\u5c71 | 2025\u5e7412\u670812\u65e5]\u00a0\u2013 \u81f4\u529b\u65bc\u958b\u767c\u4e0b\u4e00\u4ee3\u816b\u7624\u53ca\u81ea\u8eab\u514d\u75ab\u75be\u75c5\u514d\u75ab\u7642\u6cd5\u7684\u5168\u7403\u81e8\u5e8a\u968e\u6bb5\u751f\u7269\u6280\u8853\u516c\u53f8\u6f22\u5eb7\u751f\u6280\uff08TPEx: 7827\uff09\u5ba3\u4f48\uff0c\u5176\u4e3b\u529b\u5275\u65b0\u878d\u5408\u86cb\u767d\u751f\u7269\u85e5HCB101\u7684\u81e8\u5e8a\u6578\u64da\uff0c\u5df2\u88ab\u9074\u9078\u70ba2025\u5e74\u6b50\u6d32\u816b\u7624\u5b78\u6703 (ESMO, <a href=\"https:\/\/www.bing.com\/ck\/a?!&amp;&amp;p=3b872c830bd50fa0e30213714166fec0f03893e56a881b761046ad0e951b26d3JmltdHM9MTc2NTMyNDgwMA&amp;ptn=3&amp;ver=2&amp;hsh=4&amp;fclid=18a0c39f-6ae7-6089-25ff-d5c56b5a6196&amp;psq=esmo+%e5%ad%b8%e6%9c%83&amp;u=a1aHR0cHM6Ly93d3cuZXNtby5vcmcv&amp;ntb=1\" target=\"_blank\" rel=\"noopener\">European Society For Medical Oncology<\/a>) \u514d\u75ab\u816b\u7624\u5b78\u5927\u6703 (Immuno-Oncology Congress) \u7684\u5c0f\u578b\u53e3\u982d\u7c21\u5831\uff0c\u4e26\u65bc\u82f1\u570b\u502b\u6566\u8209\u884c\u3002\u4eca\u5e74\u50c5\u670926\u7bc7\u6458\u8981\u7372\u6b64\u5831\u544a\u8cc7\u683c\uff0c\u9019\u610f\u5473\u8457\u6f22\u5eb7\u751f\u6280\u9996\u6b21\u5728\u570b\u969b\u9802\u7d1a\u816b\u7624\u5b78\u8853\u6703\u8b70\u4e0a\u9032\u884c\u81e8\u5e8a\u8cc7\u6599\u53e3\u982d\u5831\u544a\uff0c\u662f\u5176\u7e7c2022\u5e74\u5728\u514d\u75ab\u6cbb\u7642\u5b78\u6703\u5927\u6703(SITC, Society for Immunotherapy of Cancer) \u4e0a\u5831\u544aHCB101\u81e8\u5e8a\u524d\u8cc7\u6599\u5f8c\u7684\u53c8\u4e00\u91cd\u5927\u91cc\u7a0b\u7891\u3002<\/p>\n<p>ESMO\u514d\u75ab\u816b\u7624\u5b78\u5927\u6703\u662f\u6b50\u6d32\u5c08\u6ce8\u65bc\u514d\u75ab\u816b\u7624\u79d1\u5b78\u7684\u9996\u8981\u76db\u6703\uff0c\u8207\u6db5\u84cb\u66f4\u5ee3\u6cdb\u816b\u7624\u9818\u57df\u7684 ESMO \u5e74\u5ea6\u5927\u6703\u4e0d\u540c\uff0cESMO \u5e74\u6703\u805a\u7126\u65bc\u5168\u65b9\u4f4d\u7684\u816b\u7624\u5b78\u7814\u7a76\u8207\u81e8\u5e8a\u9032\u5c55\uff0c\u800c\u514d\u75ab\u816b\u7624\u5b78\u5927\u6703\u5247\u5c08\u6ce8\u65bc\u514d\u75ab\u6a5f\u5236\u3001\u8f49\u8b6f\u91ab\u5b78\u5275\u65b0\uff0c\u4ee5\u53ca\u6db5\u84cb\u5148\u5929\u8207\u9069\u61c9\u6027\u514d\u75ab\u7684\u4e0b\u4e00\u4ee3\u6cbb\u7642\u7b56\u7565\u3002<\/p>\n<p><strong>\u5831\u544a\u8a73\u60c5\uff1a<\/strong><\/p>\n<ul>\n<li>\u6458\u8981\u7de8\u865f\uff1a242MO<\/li>\n<li>\u6a19\u984c\uff1aHCB101\uff0c\u4e00\u6b3e\u5dee\u7570\u5316\u7684SIRP\u03b1\u878d\u5408\u86cb\u767d\uff0c\u5728\u5be6\u9ad4\u7624\u548c\u6dcb\u5df4\u7624\u4e2d\u986f\u793a\u51fa\u826f\u597d\u7684\u5b89\u5168\u6027\u548c\u65e9\u671f\u6297\u816b\u7624\u6d3b\u6027<\/li>\n<li>\u7b2c\u4e00\u4f5c\u8005\uff1a\u752f\u65b9\u73b2\u535a\u58eb\uff0c\u6ff1\u5dde\u91ab\u5b78\u9662\u9644\u5c6c\u91ab\u9662<\/li>\n<li>\u6642\u9593\uff1a2025\u5e7412\u670811\u65e5\uff0c11:45 \u2013 12:45\uff08GMT\uff09<\/li>\n<li>\u5730\u9ede\uff1a\u502b\u6566\u4f0a\u8389\u838e\u767d\u4e8c\u4e16\u5973\u738b\u4e2d\u5fc3 (Whittle Room)<\/li>\n<li>\u5831\u544a\u4eba\uff1a\u9678\u82f1\u660e\u535a\u58eb (Alvin Luk) \u2013 \u96c6\u5718\u7e3d\u88c1\u517c\u91ab\u7642\u9577\uff0c2025\u5e74\u300a\u6642\u4ee3\u300b\u9031\u520a\u5065\u5eb7\u9818\u57df\u767e\u5927\u5f71\u97ff\u529b\u4eba\u7269<\/li>\n<\/ul>\n<p>\u201c\u8fd1\u5341\u5e74\u4f86\uff0cCD47\u7642\u6cd5\u7684\u74f6\u9838\u4e26\u975e\u751f\u7269\u5b78\u6a5f\u5236\u6709\u8aa4\uff0c\u800c\u5728\u65bc\u5206\u5b50\u8a2d\u8a08\u672c\u8eab\u96e3\u4ee5\u540c\u6642\u9867\u53ca\u5b89\u5168\u6027\u8207\u6709\u6548\u6027\uff0c\u5c24\u5176\u662f\u5728\u514d\u75ab\u2018\u51b7\u2019\u816b\u7624\u4e2d\uff0c\u201d\u6f22\u5eb7\u751f\u6280\u5275\u59cb\u4eba\u3001\u8463\u4e8b\u9577\u517c\u57f7\u884c\u9577\u5289\u4e16\u9ad8\u535a\u58eb\u8868\u793a\u3002\u201cHCB101\u5f9e\u6839\u672c\u4e0a\u5c31\u662f\u70ba\u4e86\u89e3\u6c7a\u9019\u4e00\u554f\u984c\u800c\u8a2d\u8a08\u3002\u901a\u904eAI\u5f15\u5c0e\u7684\u7d50\u69cb\u5efa\u6a21\uff0c\u6211\u5011\u767c\u73fe\u4e86\u4e09\u500b\u80fd\u91cd\u5851SIRP\u03b1\u8207CD47\u76f8\u4e92\u4f5c\u7528\u7684\u6838\u5fc3\u7a81\u8b8a\uff0c\u5f9e\u800c\u5c07\u7b2c\u4e00\u4ee3\u548c\u7b2c\u4e8c\u4ee3\u65b9\u6cd5\u7684\u512a\u52e2\u6574\u5408\u5728\u4e00\u500b\u7368\u7279\u7684\u5dee\u7570\u5316\u5206\u5b50\u4e2d\u3002\u6b64\u6b21\u7372\u9078ESMO\u514d\u75ab\u816b\u7624\u5b78\u5927\u6703\u50c5\u6709\u768426\u9805\u5fae\u578b\u53e3\u982d\u5831\u544a\u4e4b\u4e00\uff0c\u9032\u4e00\u6b65\u5370\u8b49\u4e86\u9818\u57df\u5c0d\u6b64\u5dee\u7570\u5316\u7684\u8a8d\u53ef\u3002\u6191\u85c9\u5176\u7d14\u6de8\u7684\u5b89\u5168\u6027\u3001\u5f37\u5927\u7684\u9776\u9ede\u7d50\u5408\u529b\u53ca\u5728\u51b7\u816b\u7624\u4e2d\u7684\u65e9\u671f\u6d3b\u6027\uff0cHCB101\u6b63\u5d1b\u8d77\u70ba\u4e00\u500b\u771f\u6b63\u7684\u5de8\u566c\u7d30\u80de\u6aa2\u67e5\u9ede\u57fa\u77f3\u7642\u6cd5\u2014\u2014\u6b63\u5982PD-1\/PD-L1\u66fe\u7d93\u6539\u8b8aT\u7d30\u80de\u816b\u7624\u5b78\u4e00\u6a23\u3002\u201d<\/p>\n<p>&nbsp;<\/p>\n<p><strong>\u53e3\u982d\u5831\u544a\u95dc\u9375\u8cc7\u6599\u4eae\u9ede<\/strong><\/p>\n<p>\u55ae\u85e5\u6cbb\u7642\u7814\u7a76 (HCB101-101; NCT05892718)<\/p>\n<ul>\n<li>\u5b89\u5168\u6027\u5353\u8d8a\uff1a\u572812\u500b\u5291\u91cf\u4f47\u5217\u4e2d\uff08\u6700\u9ad8\u81f336 mg\/kg\uff0c\u6bcf\u9031\u4e00\u6b21\uff09\u5747\u986f\u793a\u51fa\u5c0d\u8840\u7d30\u80de\u5f71\u97ff\u8f15\u5fae\u7684\u7279\u6027\u3002<\/li>\n<li>\u7121\u51fa\u8840\u4e8b\u4ef6\u6216\u514d\u75ab\u76f8\u95dc\u6bd2\u6027\uff1a\u5927\u591a\u6578\u6cbb\u7642\u76f8\u95dc\u4e0d\u826f\u4e8b\u4ef6\u70ba1-2\u7d1a\u3002<\/li>\n<li>\u7dda\u6027\u85e5\u4ee3\u52d5\u529b\u5b78\uff1a\u534a\u8870\u671f\u7d043\u5929\uff0c\u5728\u5291\u91cf\u22658 mg\/kg\u6642\uff0c\u53d7\u9ad4\u4f54\u6709\u7387&gt;90%\u3002<\/li>\n<li>\u6301\u4e45\u7684\u6297\u816b\u7624\u6d3b\u6027\uff0c\u5305\u62ec\u4ee5\u4e0b\u78ba\u8a8d\u7684\u90e8\u5206\u7de9\u89e3\uff1a\n<ul>\n<li>\u982d\u9838\u9c57\u72c0\u7d30\u80de\u764c\uff1a\u816b\u7624\u7e2e\u5c0f\u7d0442%\uff0c\u7de9\u89e3\u6301\u7e8c\u226532\u5468\u3002<\/li>\n<li>\u908a\u7de3\u5340\u6dcb\u5df4\u7624\uff1a\u816b\u7624\u7e2e\u5c0f\u7d0489%\uff0c\u7de9\u89e3\u6301\u7e8c\u226516\u5468\u3002<\/li>\n<\/ul>\n<\/li>\n<li>\u75be\u75c5\u7a69\u5b9a\u9577\u90544-9\u500b\u6708\uff1a\u898b\u65bc\u7d50\u76f4\u8178\u764c\u3001\u5375\u5de2\u764c\u3001\u975e\u5c0f\u7d30\u80de\u80ba\u764c\u548c\u8089\u7624\u60a3\u8005\u3002<\/li>\n<\/ul>\n<p><strong>\u806f\u5408\u6cbb\u7642\u7814\u7a76 (HCB101-201; NCT06771622)<\/strong><\/p>\n<ul>\n<li>\u8010\u53d7\u6027\u826f\u597d\uff1a\u5728\u80c3\u764c\u3001\u4e09\u9670\u6027\u4e73\u764c\u3001\u7d50\u76f4\u8178\u764c\u548c\u982d\u9838\u764c\u4e2d\u5747\u8868\u73fe\u826f\u597d\u3002<\/li>\n<li>\u7121\u65b0\u7684\u5b89\u5168\u6027\u4fe1\u865f\uff1a\u5728\u6240\u6709\u8a55\u4f30\u7684\u806f\u5408\u65b9\u6848\u4e2d\u5747\u672a\u51fa\u73fe\u3002<\/li>\n<li>\u5168\u8840\u7d30\u80de\u6e1b\u5c11\u5b8c\u5168\u6b78\u56e0\u65bc\u5316\u7642\uff0c\u800c\u975eHCB101\u3002<\/li>\n<li>\u4e8c\u7dda\u80c3\u764c\uff1a\n<ul>\n<li>\u5ba2\u89c0\u7de9\u89e3\u7387 (ORR) \u905458.3%\uff087\/12\uff09\uff0c\u75be\u75c5\u63a7\u5236\u7387 (DCR) \u9054100%\u3002<\/li>\n<li>\u816b\u7624\u76f4\u5f91\u6700\u5927\u7e2e\u5c0f\u5e45\u5ea6\u905478.2%\u3002<\/li>\n<\/ul>\n<\/li>\n<li>\u4e00\u7ddaHER2\u967d\u6027\u80c3\u764c\uff1a\u5ba2\u89c0\u7de9\u89e3\u7387 (ORR) \u70ba33%\uff081\/3\uff09\u3002<\/li>\n<li>\u4e00\u7dda\u4e09\u9670\u6027\u4e73\u764c\uff1a\u5ba2\u89c0\u7de9\u89e3\u7387 (ORR) \u70ba33%\uff082\/6\uff09\uff0c\u75be\u75c5\u63a7\u5236\u7387 (DCR) \u9054100%\u3002<\/li>\n<\/ul>\n<p>\u6f22\u5eb7\u751f\u6280\u96c6\u5718\u7e3d\u88c1\u517c\u91ab\u7642\u9577\u9678\u82f1\u660e\u535a\u58eb\u88dc\u5145\u9053\uff1a\u201cHCB101\u5728\u6b64\u7814\u767c\u968e\u6bb5\u6240\u986f\u793a\u7684\u65e9\u671f\u7642\u6548\u4fe1\u865f\u683c\u5916\u5f15\u4eba\u6ce8\u76ee\u3002\u5728\u6a19\u6e96\u7642\u6cd5\u5ba2\u89c0\u7de9\u89e3\u7387 (ORR) \u50c5\u7d0428%\u7684\u4e8c\u7dda\u80c3\u764c\u4e2d\uff0cHCB101\u806f\u5408\u65b9\u6848\u7684\u5ba2\u89c0\u7de9\u89e3\u7387 (ORR) \u8d85\u904e58%\uff0c\u75be\u75c5\u63a7\u5236\u7387 (DCR) \u9054\u5230100%\uff0c\u816b\u7624\u7e2e\u5c0f\u5e45\u5ea6\u63a5\u8fd178%\u3002\u9019\u4e9b\u7d50\u679c\u4e26\u975e\u5fae\u5c0f\u7684\u6539\u5584\uff0c\u800c\u662f\u986f\u8457\u8d85\u8d8a\u4e86\u9810\u671f\uff0c\u53cd\u6620\u4e86\u5f37\u800c\u6709\u529b\u7684\u5de8\u566c\u7d30\u80de\u6aa2\u67e5\u9ede\u555f\u52d5\u3002\u7d50\u5408\u5b89\u5168\u6027\u548c\u6301\u7e8c\u7684\u53d7\u9ad4\u4f54\u6709\u7387\uff0c\u9019\u4e9b\u8cc7\u6599\u4f7f\u6211\u5011\u6709\u4fe1\u5fc3\u5c07\u958b\u767c\u91cd\u9ede\u9328\u5b9a\u5728\u4e8c\u7dda\u75be\u75c5\uff0c\u4e26\u62d3\u5c55\u81f3\u5c0d\u7de9\u89e3\u6df1\u5ea6\u548c\u6301\u4e45\u6027\u8981\u6c42\u6700\u9ad8\u7684\u4e00\u7dda\u53ca\u570d\u624b\u8853\u671f\u6cbb\u7642 (perioperative treatment\uff0c\u624b\u8853\u524d\u5f8c\u7684\u6cbb\u7642) \u9818\u57df\u3002\u201d<\/p>\n<p>&nbsp;<\/p>\n<p><strong>\u95dc\u65bcHCB101\uff1a\u4e00\u6b3e\u65b0\u4e00\u4ee3SIRP\u03b1 Fc\u878d\u5408\u86cb\u767d<\/strong><br \/>\nHCB101\u662f\u4e00\u6b3e\u57fa\u65bc\u6f22\u5eb7\u751f\u6280FBDB\u2122\u5e73\u81fa\u958b\u767c\u76843.5\u4ee3\u5de5\u7a0b\u5316SIRP\u03b1-Fc\u878d\u5408\u86cb\u767d\uff0c\u5177\u6709\u5b8c\u6574\u7684IgG4 Fc\u9aa8\u67b6\u3002\u5176\u8a2d\u8a08\u65e8\u5728\u9078\u64c7\u6027\u9776\u5411CD47\uff0c\u540c\u6642\u6975\u5927\u964d\u4f4e\u8207\u7d05\u8840\u7403\u7684\u7d50\u5408\uff0c\u5f9e\u800c\u907f\u514d\u4e86\u9650\u5236\u65e9\u671f\u6297CD47\u85e5\u7269\u958b\u767c\u7684\u8ca7\u8840\u548c\u8840\u5c0f\u677f\u6e1b\u5c11\u554f\u984c\uff0c\u540c\u6642\u4fdd\u7559\u4e86\u5f37\u5927\u5730\u555f\u52d5\u5de8\u566c\u7d30\u80de\u53ca\u53ec\u96c6\u4e0b\u6e38T\u7d30\u80de\u7684\u529f\u80fd\u3002\u95dc\u9375\u5dee\u7570\u5316\u512a\u52e2\u5305\u62ec\uff1a<\/p>\n<ul>\n<li>\u5353\u8d8a\u5b89\u5168\u6027\uff1a\u5291\u91cf\u9ad8\u905430-36 mg\/kg\u4ecd\u5c0d\u5168\u8840\u7d30\u80de\u5f71\u97ff\u8f15\u5fae\u3002<\/li>\n<li>\u9ad8\u6548\u7684\u9776\u9ede\u7d50\u5408\uff1a\u5728\u81e8\u5e8a\u6709\u6548\u66b4\u9732\u5291\u91cf\u4e0b\uff0c\u53d7\u9ad4\u4f54\u6709\u7387&gt;90%\u3002<\/li>\n<li>\u5f37\u5927\u7684\u514d\u75ab\u555f\u52d5\uff1a\u6709\u6548\u555f\u52d5\u5de8\u566c\u7d30\u80de\u53ca\u4e0b\u6e38T\u7d30\u80de\u3002<\/li>\n<li>\u5ee3\u6cdb\u7684\u6297\u816b\u7624\u6d3b\u6027\uff1a\u5728\u8d85\u904e80\u500bPDX\/CDX\u6a21\u578b\u53ca\u591a\u7a2e\u81e8\u5e8a\u816b\u7624\u985e\u578b\u4e2d\u6709\u6548\u3002<\/li>\n<li>\u986f\u8457\u7684\u65e9\u671f\u806f\u5408\u7642\u6548\uff1a\u5728\u5c0dCD47\u9776\u5411\u7642\u6cd5\u6b77\u53f2\u4e0a\u4e0d\u654f\u611f\u7684\u816b\u7624\u4e2d\u986f\u73fe\u3002<\/li>\n<\/ul>\n<p>\u8207\u65e9\u671f\u65b9\u6cd5\u4e0d\u540c\uff0cHCB101\u7684\u5b89\u5168\u6027\u3001\u9776\u9ede\u9078\u64c7\u6027\u548c\u53d7\u9ad4\u4f54\u6709\u7387\u7279\u5fb5\uff0c\u652f\u63f4\u5176\u4f5c\u70ba\u4e00\u7a2e\u5de8\u566c\u7d30\u80de\u6aa2\u67e5\u9ede\u57fa\u77f3\u7642\u6cd5\u4f7f\u7528\u2014\u2014\u985e\u4f3c\u65bcPD-1\/PD-L1\u6291\u5236\u5291\u5728\u816b\u7624\u5b78\u4e2d\u4f5c\u70baT\u7d30\u80de\u57fa\u77f3\u7642\u6cd5\u7684\u89d2\u8272\u3002HCB101\u8a2d\u8a08\u7528\u65bc\u8207\u73fe\u6709\u53ca\u65b0\u8208\u7684\u6cbb\u7642\u6a21\u5f0f\u5ee3\u6cdb\u806f\u7528\uff0c\u5305\u62ec\uff1a<\/p>\n<ul>\n<li>\u5316\u7642<\/li>\n<li>\u653e\u7642<\/li>\n<li>\u6297\u9ad4\u5076\u806f\u85e5\u7269<\/li>\n<li>\u6297PD-1\/PD-L1\u6aa2\u67e5\u9ede\u6291\u5236\u5291<\/li>\n<li>\u6297VEGF\u6291\u5236\u5291<\/li>\n<li>\u6297EGFR\u7642\u6cd5<\/li>\n<li>\u6297HER2\u65b9\u6848<\/li>\n<\/ul>\n<p>\u9019\u7a2e\u591a\u529f\u80fd\u6027\u4f7fHCB101\u6210\u70ba\u4e00\u500b\u6a21\u7d44\u5316\u7684\u3001\u4e0b\u4e00\u4ee3\u514d\u75ab\u816b\u7624\u5143\u4ef6\uff0c\u6709\u671b\u589e\u5f37\u591a\u7a2e\u6cbb\u7642\u65b9\u6848\u5728\u5be6\u9ad4\u7624\u548c\u8840\u6db2\u60e1\u6027\u816b\u7624\u4e2d\u7684\u7642\u6548\u3002<\/p>\n","protected":false},"excerpt":{"rendered":"<p>HanchorBio Announces Oral Presentation of HCB101 at the [&hellip;]<\/p>\n","protected":false},"featured_media":2199,"template":"","news-category":[41,42],"class_list":["post-2201","news","type-news","status-publish","has-post-thumbnail","hentry","news-category-events","news-category-development-progress"],"acf":[],"_links":{"self":[{"href":"https:\/\/www.hanchorbio.com\/zh-hans\/wp-json\/wp\/v2\/news\/2201","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.hanchorbio.com\/zh-hans\/wp-json\/wp\/v2\/news"}],"about":[{"href":"https:\/\/www.hanchorbio.com\/zh-hans\/wp-json\/wp\/v2\/types\/news"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.hanchorbio.com\/zh-hans\/wp-json\/wp\/v2\/media\/2199"}],"wp:attachment":[{"href":"https:\/\/www.hanchorbio.com\/zh-hans\/wp-json\/wp\/v2\/media?parent=2201"}],"wp:term":[{"taxonomy":"news-category","embeddable":true,"href":"https:\/\/www.hanchorbio.com\/zh-hans\/wp-json\/wp\/v2\/news-category?post=2201"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}